StockNews.AI
SIGA
StockNews.AI
168 days

SIGA to Host Business Update Call on March 11, 2025 Following Release of Fourth-Quarter and Full Year 2024 Financial Results

1. SIGA to host conference call on March 11, 2025. 2. CEO Diem Nguyen and CFO Daniel Luckshire will present updates. 3. Live webcast accessible on SIGA's Investor Relations website. 4. SIGA focuses on infectious disease treatments, particularly orthopoxviruses. 5. TPOXX® is SIGA's flagship antiviral medicine for smallpox and related diseases.

Earnings
+2.23%Current Return
VS
-0.47%S&P 500
$5.3903/04 07:35 AM EDTEvent Start
$5.5103/05 02:01 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

The scheduled call may provide essential updates, but lacks immediate financial implications.

How important is it?

While the call may offer insights, major impacts depend on presented information.

Why Short Term?

The conference call may lead to immediate investor reactions based on updates.

Related Companies

GSKMRNA
March 04, 2025 07:30 ET  | Source: SIGA Technologies Inc. NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, March 11, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1152574. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit www.siga.com.

Related News